The Cancer Genome Atlas consortium and other sequencing projects have found that the KEAP1-NRF2 degradation pathway is frequently altered in cancer, by either gain-of-function mutations in NRF2 or loss-of-function mutations in KEAP1 or CUL3 [22, 23]. Here, NFE2L2 is linked to cancer.